Management has positioned bezuclastinib as a potential alternative to Blueprint Medicines' (BPMT) Ayvakit. This PDGFRα/c-KIT ...
Dr Pietro A. Canetta illustrates recent advances in IgA nephropathy and focal segmental glomerulosclerosis (FSGS) with two ...
Jeff Johnston, Amanda Stewart, Anita Berry and Lauren Lange represented 64 clients in Q3. The Hillsborough County Sheriff’s ...
Fintel reports that on November 28, 2025, HC Wainwright & Co. reiterated coverage of Travere Therapeutics (NasdaqGM:TVTX) ...
Renalys Pharma reports positive results from phase III study of sparsentan in Japanese patients with IgA nephropathy: Tokyo, Japan Friday, November 28, 2025, 13:00 Hrs [IST] Renal ...
Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.
Investor's Business Daily on MSN
Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025
Travere Therapeutics stock has doubled, and then some, in 2025 even as competition heats up for its bread-and-butter drug, ...
Anti-APRIL antibody Voyxact (sibeprenlimab) has been approved by the US regulator to reduce proteinuria in adults with ...
Travere Therapeutics' market cap has more than doubled in six months, reflecting confidence in FILSPARI's role in treating ...
In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy (N=35), the percent change from baseline in the 24-hour urine ...
Detailed price information for Varex Imaging Corp (VREX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results